Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
BioCentury's streaming commentary on biotech industry trends, plus interviews with leading KOLs. For three decades, BioCentury has given biopharma executives, investors and institutions the power to make business-critical decisions through independent, deep-dive analysis; high-quality data; industry-leading business intelligence; and global conferences.
Episode | Date |
---|---|
Ep. 227 - Defending Accelerated Approval. Plus: Endpoint Innovation & AIM Amiss
|
Apr 22, 2024 |
Ep. 226 - Vertex’s Alpine Buy, Goldman’s Venture & IRA Tea Leaves
|
Apr 16, 2024 |
Ep. 225 - 2Q Markets Preview & AACR Takeaways
|
Apr 08, 2024 |
Ep. 224 - Biotech IPOs, Avalon & FDA at SCOTUS
|
Apr 02, 2024 |
Ep. 223 - Biosecure, Bruce Booth & Ultrarare Drugs
|
Mar 26, 2024 |
Ep. 222 - Crowley’s Vision for BIO, Plus: MASH & CAR Ts
|
Mar 18, 2024 |
Ep. 221 - China Biocontroversy, Plus: Diversity Matters
|
Mar 12, 2024 |
Ep. 220 - Biotech’s Financing Flurry & Distillery Spotlight
|
Mar 05, 2024 |
Ep. 219 - East-West Summit Preview
|
Feb 28, 2024 |
Ep. 218 - Bob Nelsen Insights, TL1A, Rare Diseases
|
Feb 27, 2024 |
Ep. 217 - Safer CAR Ts & World’s First TIL Therapy
|
Feb 21, 2024 |
Ep. 216 - Anti-China Biotech Policy: Biosecure & Beyond
|
Feb 16, 2024 |
Ep. 215 - ADCs, Psychedelics & IPOs
|
Feb 13, 2024 |
Ep. 214 - BMS’s Patent Cliff, Congress Targets China Biotech
|
Feb 06, 2024 |
Ep. 213 - Biotech IPOs & IL-18 Momentum
|
Jan 30, 2024 |
Ep. 212 - 2024 Buyside View & Arnold Ventures' Impact
|
Jan 23, 2024 |
Ep. 211 - 2024 Markets Preview, Woodcock's Legacy
|
Jan 17, 2024 |
Ep. 210 - J.P. Morgan Healthcare Conference Wrap
|
Jan 13, 2024 |
Ep. 209 - Biotech M&A, Innovation, Public Policy in 2024
|
Jan 05, 2024 |
Ep. 208 - XBI Rally, ASH Highlights & '24 Picks
|
Dec 19, 2023 |
Ep. 207 - Sickle Cell, AbbVie Deals, BIO CEO, March-in
|
Dec 12, 2023 |
Ep. 206 - Roche, AbbVie Deals; Plus: FDA & CAR T
|
Dec 05, 2023 |
Ep. 205 - Radiotherapy Deep Dive; Plus: Congress, BioNTech
|
Nov 28, 2023 |
Ep. 204 - First CRISPR Approval & IRA’s Lost Orphans
|
Nov 20, 2023 |
Ep. 203 - POC for Verve? Plus: IRA & East-West Deals
|
Nov 14, 2023 |
Ep. 202 - A DMD Decision & Endpoint Innovation
|
Nov 07, 2023 |
Ep. 201 - ESMO, NIH & IRA
|
Oct 30, 2023 |
Ep. 200 - Merck-Daiichi, Roche-Roivant, Base Editors
|
Oct 24, 2023 |
Ep. 199 - China Summit Preview
|
Oct 20, 2023 |
Ep. 198 - Novartis Finds Focus & EU Pharma Law
|
Oct 16, 2023 |
Ep. 197 - Mirati Takeout & 4Q23 Financial Markets Preview
|
Oct 09, 2023 |
Ep. 196 - CAR T's Next Act & Hudson's Vision for Sanofi
|
Oct 03, 2023 |
Ep. 195 - East-West Summit Preview
|
Sep 25, 2023 |
Ep. 194 - IPO Outlook & IRA Lawsuits
|
Sep 19, 2023 |
Ep. 193 - East-West CAR T Deals, Plus: Amgen-FTC
|
Sep 12, 2023 |
Ep. 192 - Tier-jumpers: a Back to School Overview
|
Sep 05, 2023 |
Ep. 191 - Circular RNA, Psychedelics, & Upcoming BioCentury Summits
|
Aug 22, 2023 |
Ep. 190 - Obesity Mechanisms, Noubar Takeaways, Scleroderma Platform Trial
|
Aug 14, 2023 |
Ep. 189 - Biogen-Sage Setback, Biotech IPOs, Sanofi Digital
|
Aug 07, 2023 |
Ep. 188 – Pharma deals; Plus: Genentech, Leerink Conversations
|
Jul 31, 2023 |
Ep. 187 - Alnylam-Roche; Plus: Insights on the IRA, FTC
|
Jul 24, 2023 |
Ep. 186 - 3Q Markets Preview, Donanemab & Lilly-Versanis
|
Jul 17, 2023 |
Ep. 185 - Leqembi's Launch, Biotech IPOs, Sarepta Approval
|
Jul 11, 2023 |
Ep. 184 - Califf's FDA reforms & Polaris' Schulman
|
Jun 26, 2023 |
Ep. 183 - EMA's Cooke, What's Next for IPSCs, & Leerink is Back
|
Jun 19, 2023 |
Ep. 182 - Merck’s IRA suit, Leqembi and MCEDs at ASCO
|
Jun 13, 2023 |
Ep. 181 - Highlights from ASCO
|
Jun 05, 2023 |
Ep. 180 - ASCO, Neuropsych & the IRA
|
May 30, 2023 |
Ep. 179 - DMD Gene Therapies, CBER & NIH
|
May 23, 2023 |
Ep. 178 - Live from Bio€quity, Part 2
|
May 16, 2023 |
Ep. 177 - Live from Bio€quity, Part 1
|
May 15, 2023 |
Ep. 176 - Bio€quity Europe 2023 Preview: Crafting a European Playbook for Success
|
May 09, 2023 |
Ep. 175 - Acelyrin IPO, Alzheimer's Data & Digital Endpoints
|
May 09, 2023 |
Ep. 174 - EC Pharma Law, ALS Biomarker, Astellas' Iveric Deal
|
May 01, 2023 |
Ep. 173 - EU VC Funds, Abortion Drug Ruling, IRA Insights
|
Apr 25, 2023 |
Ep. 172 - AACR Insights
|
Apr 20, 2023 |
Ep. 171 - 2Q Markets Preview, Abortion Drug Rulings, Gilead Oncology
|
Apr 17, 2023 |
Ep. 170 - Abortion Ruling & FDA; New VC Funds; IRA
|
Apr 10, 2023 |
Ep. 169 - FTC & Illumina, Plus: PCSK9s at SCOTUS
|
Apr 03, 2023 |
Ep. 168 - VCs' Take on SVB & New ALS Endpoint
|
Mar 27, 2023 |
Ep. 167 - The IRA, T Cell Therapies & The Distillery
|
Mar 21, 2023 |
Ep. 166 - SVB Shakeout: Next Steps for Biotech
|
Mar 17, 2023 |
Ep. 165 - SVB Fallout, Plus: Pfizer-Seagen
|
Mar 13, 2023 |
Ep. 164 - Viehbacher’s Vision, NK Cells & Bat Biotech
|
Mar 07, 2023 |
Ep. 163 - EU Pharma Law Overhaul, Abortion Drug Ruling, Dunn's Departure
|
Feb 28, 2023 |
Ep. 162 - New CMS Payment Models, China Markets Outlook, & Zhang's Latest Start-Up
|
Feb 21, 2023 |
Ep. 161 - New Cancer Paradigms, Distilling Innovations, & IPOs
|
Feb 13, 2023 |
Ep. 160 - Dose Optimization, Clinical Trials Diversity and QALYs
|
Feb 07, 2023 |
Ep. 159 - BIO's Priorities, ESG & Venture Trends
|
Jan 31, 2023 |
Ep. 158 - CAR T Manufacturing & Orphan Drugs
|
Jan 24, 2023 |
Ep. 157 - 2023 Markets Outlook & Buyside Picks
|
Jan 18, 2023 |
Ep. 156 - JPM Highlights & Alzheimer's Takeaways
|
Jan 09, 2023 |
Ep. 155 - U.K. Biotech, Aduhelm, 2022 Approval Trends
|
Jan 04, 2023 |
Ep. 154 - Madrigal in NASH, Moderna & Neoantigens, the Distillery
|
Dec 20, 2022 |
Ep. 153 - The Inflation Reduction Act
|
Dec 19, 2022 |
Ep. 152 - Amgen's Horizon Takeout. Plus: ASH, SERDs
|
Dec 13, 2022 |
Ep. 151 - Alzheimer's Takeaways, U.K. Biotech, Charles Forum
|
Dec 06, 2022 |
Ep. 150 - Model Term Sheets, Pragmatic Trials & Gene Therapy Prices
|
Nov 28, 2022 |
Ep. 149 - Takeaways from the East-West Summit
|
Nov 21, 2022 |
Ep. 148 - East-West Summit Highlights Part 2
|
Nov 18, 2022 |
Ep. 147 - East-West Summit Highlights Part 1
|
Nov 16, 2022 |
Ep. 146 - What's Next in Washington, Plus: SITC & the Distillery
|
Nov 15, 2022 |
Ep. 145 - What's Next for BIO, Plus: Pfizer, GSK
|
Nov 07, 2022 |
Ep. 144 - Alnylam's IRA Pause, Plus Argenx & Accumulus
|
Oct 31, 2022 |
Ep. 143 - East-West Summit Preview
|
Oct 28, 2022 |
Ep. 142 - Lundbeck, Biogen, Biden & Biomanufacturing, Nora Volkow
|
Oct 25, 2022 |
Ep. 141 - Neoantigen Vaccines, Drug Pricing, U.S.-China & U.K. Turmoil
|
Oct 17, 2022 |
Ep. 140 - Turbulence at BIO, Plus 4Q Preview & the Distillery
|
Oct 11, 2022 |
Ep. 139 - Wins in Neurodegeneration, U.S.-China & Life Science Cares
|
Oct 04, 2022 |
Ep. 138 - FDA User Fee Endgame, East-West Summit & Biogen
|
Sep 27, 2022 |
Ep. 137 - Intellia's Data, IRA's Orphan Impact, CFIUS Order
|
Sep 19, 2022 |
Ep. 136 - IRA, KRAS & ESMO
|
Sep 13, 2022 |
Ep 135 Pt. 5 - A Portrait of Biopharma's New Leaders
|
Sep 02, 2022 |
Ep 135 Pt. 4 - Filling Biopharma's Talent Pipeline
|
Sep 01, 2022 |
Ep 135 Pt. 3 - Rising Leaders & the VC View on Talent
|
Aug 31, 2022 |
Ep 135 Pt. 2 - CEOs in the Spotlight. Plus: Women Leaders, DEI
|
Aug 30, 2022 |
Ep 135 Pt. 1 - Back to School 2022 Overview
|
Aug 29, 2022 |
Ep. 134 - Preclinical Deal Making, Bluebird's Approval & Epigenome Editing
|
Aug 22, 2022 |
Ep. 133 - Financing Thaw? Plus: Protein Design & China Audits
|
Aug 16, 2022 |
Ep. 132 - M&A & Data: recipe for a rebound?
|
Aug 09, 2022 |
Ep. 131 - Seagen, New Modalities & Structure
|
Aug 02, 2022 |
Ep. 130 - Steady as a Roche. Plus: Washington Turbulence
|
Jul 25, 2022 |
Ep. 129 - Burr Bill, Novartis Makeover, ALS Update
|
Jul 19, 2022 |
Ep. 128 - Financial Markets Forecast, AAV Toxicity & Drug Pricing
|
Jul 12, 2022 |
Ep. 127 - TeneoTwo, Lightspeed, Arch & The Distillery
|
Jul 06, 2022 |
Ep. 126 - Growing Galapagos, Plus Abortion & Biopharma
|
Jun 28, 2022 |
Ep. 125 - Next Steps for ARPA-H
|
Jun 21, 2022 |
Ep. 124 - CRISPR's High Bar, Private Equity Inroads and the Distillery
|
Jun 13, 2022 |
Ep. 123 - Fixing FDA's Broken Advisory Panels
|
Jun 08, 2022 |
Ep. 122 - ASCO's Advances & Fixes for FDA's AdComms
|
Jun 07, 2022 |
Ep. 121 - ASCO, CRISPR IP & CStone
|
Jun 01, 2022 |
Ep. 120 - Next-gen NK cells, Plus Woodcock & BMS’s Russian Withdrawal
|
May 23, 2022 |
Ep. 119 - Bio€quity Recap, Part 2
|
May 19, 2022 |
Ep. 118 - Bio€quity Recap, Part 1
|
May 18, 2022 |
Ep. 117 - Sofinnova Partners’ Growth Deal, Plus Distillery on Tap
|
May 17, 2022 |
Ep. 116 - The Road to Bio€quity 2022: Navigating Through Talent & Capital Headwinds
|
May 12, 2022 |
Ep. 115 - FDA Reform on Deck, Plus Translation at Howard
|
May 10, 2022 |
Ep. 114 - Hutchmed Setback, FDA in Focus, HilleVax's IPO
|
May 03, 2022 |
Ep. 113 - Nkarta’s Breakthrough, Hatch’s Legacy & Shanghai’s Lockdown
|
Apr 26, 2022 |
Ep. 112 - Digesting DDR Data; Plus Sharpless’ Legacy, McKinsey’s Conflicts
|
Apr 19, 2022 |
Ep. 111 - Seeking Green Shoots Amid Biotech’s Gloom
|
Apr 14, 2022 |
Ep. 110 - Aduhelm’s Lessons, Plus Distillery Discoveries, Rare Disease Innovation
|
Apr 12, 2022 |
Ep. 109 - What's Next for Novartis? Plus: AACR, Merck KGaA
|
Apr 05, 2022 |
Ep. 108 - AACR Preview for CAR Ts in Solid Tumors; Plus FDA Weighs in on Data for ALS Ad Com
|
Mar 29, 2022 |
Ep. 107 - A Tale of Two Targets: LAG3, IL-2; Plus Alternatives to Cash Up
|
Mar 22, 2022 |
Ep. 106 - China's C-suite Hears FDA, Plus AACR, ARPA-H
|
Mar 15, 2022 |
Ep. 105 - War Pulls Biotech to Ukraine, Out of Russia
|
Mar 08, 2022 |
Ep. 104 - Biotech Shows Support for Ukraine, Plus Latest Intellia Data
|
Mar 01, 2022 |
Ep. 103 - Califf’s Priorities for Second Stint as FDA Commissioner
|
Feb 23, 2022 |
Ep. 102 - What FDA's Tyvyt Precedent Means for China; plus Translational Trendspotting
|
Feb 15, 2022 |
Ep. 101 - Of Biotech Bears, Pazdur & PDUFA
|
Feb 08, 2022 |
Ep. 100 - Capital markets check in; plus Belgium’s prodigal son returns
|
Feb 01, 2022 |
Ep. 99 - Introducing The BioCentury Show, Plus Califf, COVID and GSK
|
Jan 25, 2022 |
Ep. 98 - Bargain Hunting in a Rocky Market, plus Advantage, CMS
|
Jan 19, 2022 |
Ep. 97 - Buysiders' Picks, plus JPM22 roundup
|
Jan 11, 2022 |
Ep. 96 - Aduhelm, Pazdur, Pharma Digital & '21 Wrap
|
Dec 21, 2021 |
Ep. 95 - ASH's New Targets, Avistone & Washington Update
|
Dec 14, 2021 |
Ep. 94 - Woodcock's To-Do List, Maraganore's Takeaways & the Distillery
|
Dec 07, 2021 |
Ep. 93 - Omicron's Open Questions, Plus the Business Case for Ultra-rare Diseases
|
Nov 30, 2021 |
Ep. 92 - Biogen’s R&D decision, previewing TIGIT & China Summit highlights
|
Nov 22, 2021 |
Ep. 91 - China Summit Highlights: Day 2
|
Nov 18, 2021 |
Ep. 90 - China Summit Highlights: Day 1
|
Nov 17, 2021 |
Ep. 89 - Califf's Passions, RWE in China & LSP Rising
|
Nov 16, 2021 |
Ep. 88 - China Summit Preview: The Bridge to Innovation
|
Nov 10, 2021 |
Ep. 87 - Digesting Drug Pricing, Plus Access in ALS
|
Nov 09, 2021 |
Ep. 86 - Woodcock's Legacy, Plus Frazier, Bain & the Distillery
|
Nov 02, 2021 |
Ep. 85 - What's Next for CRISPR & Gene Therapy, Plus China Summit Preview
|
Oct 26, 2021 |
Ep. 84 - Why Gene Therapy's Bad Year Is a Speed Bump, Not a Dead End
|
Oct 22, 2021 |
Ep. 83 - Assessing Biogen’s ALS Miss, Plus Califf on Deck
|
Oct 18, 2021 |
Ep. 82 - 4Q Markets Preview, Plus the Future of NIH
|
Oct 12, 2021 |
Ep. 81 - Merck & the State of M&A, Plus Novartis CEO's Call to Action
|
Oct 05, 2021 |
Ep. 80 - Hong Kong Rising, Plus Varmus' POV & Biden's FDA Choice
|
Sep 28, 2021 |
Ep. 79 - ESMO, Jeito & the Latest from Washington
|
Sep 21, 2021 |
Ep. 78 - Remembering Fred Frank, Lisa Raines, Plus CRISPR, Washington Updates
|
Sep 14, 2021 |
Ep. 77 - Back to School Spotlight & Pressures on FDA
|
Sep 04, 2021 |
Ep 76 Pt. 4 - Modifying Access for Accelerated Approvals
|
Sep 01, 2021 |
Ep 76 Pt. 3 - Delivering the Evidence for Accelerated Approval
|
Sep 01, 2021 |
Ep 76 Pt. 2 - Standards of Evidence for Accelerated Approval
|
Aug 30, 2021 |
Ep 76 Pt. 1 - Accelerated Approval's Big Picture
|
Aug 30, 2021 |
Ep. 75 - Back to School Preview, plus Pfizer Eats Trillium
|
Aug 24, 2021 |
Ep. 74 - Vertex's Road Map & Innovation in MS
|
Aug 16, 2021 |
Ep. 73 - Next Up in COVID with Otello Stampacchia and Umer Raffat
|
Aug 13, 2021 |
Ep. 72 - Modality Matters: M&A Heats Up, Galbraith Maps AZ's BD
|
Aug 09, 2021 |
Ep. 71 - Lessons from China’s Market Turmoil, Plus Distillery on Tap
|
Aug 03, 2021 |
Ep. 70 - Prepping for China’s IP law with Jones Day’s Tony Chen
|
Jul 29, 2021 |
Ep. 69 - Allaying Aduhelm Concerns, Plus Master Protocols, Arvinas-Pfizer
|
Jul 27, 2021 |
Ep. 68 - Drug Pricing Pressure, Plus European Deal Trends
|
Jul 20, 2021 |
Ep. 67 - Aduhelm: a Tangled Plot; Plus, INTREPID Pandemic Planning
|
Jul 13, 2021 |
Ep. 66 - Biotechs hit 3Q with Coolers Full of Cash; plus Distillery on Tap
|
Jul 06, 2021 |
Ep. 65 - Optimism for Intellia's CRISPR Breakthrough, Concerns about Aduhelm
|
Jun 29, 2021 |
Ep. 64 - Amyloid Analysis: Stress Testing FDA's Logic on Surrogate Endpoint
|
Jun 24, 2021 |
Ep. 63 - Woodcock, Noubar and Genmab’s dealmaking: A BioCentury Podcast
|
Jun 21, 2021 |
Ep. 62 - Reflecting on the Implications of Aduhelm's Approval: A BioCentury Podcast
|
Jun 14, 2021 |
Ep. 61 - Dissecting FDA's Aducanumab Decision
|
Jun 08, 2021 |
Ep. 60 - D-Day for Aducanumab: What's at stake
|
Jun 02, 2021 |
Ep. 59 - KRAS to the Future; plus ARPA-H & EGFR
|
Jun 02, 2021 |
Ep. 58 - LAG3 Before You Leap; plus BEE21, G20 Highlights
|
May 24, 2021 |
Ep. 57 - Financing Scandinavia; plus IP Waivers, Long Covid & AAV Pays
|
May 10, 2021 |
Ep. 56 - FDA’s ODAC Bind; plus NK Cell Engagers and Company Creation in Europe
|
May 04, 2021 |
Ep. 55 - German Plays Deliver on Data, plus Accelerated Approval on Trial
|
Apr 27, 2021 |
Ep. 54 - Patient Groups’ Pandemic Pain; plus Voters’ Rights and Synthetic Lethality
|
Apr 20, 2021 |
Ep. 53 - Competence & Continuity at CDER; plus BIO 3.0, AACR and 2Q Preview
|
Apr 13, 2021 |
Ep. 52 - Memories of John Martin, plus AACR's Hot Targets & Bio€quity Europe Preview
|
Apr 06, 2021 |
Ep. 51 - Abernethy & the Obvious at FDA; Plus CEPI & EpimAb
|
Mar 30, 2021 |
Ep. 50 - FTC & the Zombie Pharma Dinosaurs; Plus: RIP José Baselga, NCATS & SPACs
|
Mar 23, 2021 |
Ep. 49 - Vaccine Vexed; Plus Assessing Lilly's Alzheimer's Data & PDUFA Preview
|
Mar 16, 2021 |
Ep. 48 - New Modality Deep Dive; plus Sharpless Speaks & Five Prime Scores
|
Mar 09, 2021 |
Ep. 47 - Whither Woodcock; plus Refresh for German Biotech & Modalities to Market
|
Mar 02, 2021 |
Ep. 46 - Pipeline plays for BMS, Rigel; plus J&J's vaccine panel & access for Africa
|
Feb 23, 2021 |
Ep. 45 - Start-Up Trends, COVID Variants and J&J's Adcomm
|
Feb 17, 2021 |
Ep. 44 - Biotech's IPO blizzard, plus GameStop, Porter Report & Vaccine Guidance
|
Feb 09, 2021 |
Ep. 43 - Europe's Next Act & the Porter Report
|
Feb 02, 2021 |
Ep. 42 - Warp Speed Reflections, Master Protocols & Biden’s COVID Plan
|
Jan 25, 2021 |
Ep. 41 - Biden's Science Team; Plus: Early Cancer Detection
|
Jan 20, 2021 |
Ep. 40 - Investors' Picks & Access to Capital in 2021
|
Jan 15, 2021 |
Ep. 39 - COVID Accountability, Biden's Bidding & Start-up Season
|
Jan 12, 2021 |
Ep. 38 - Crucible of COVID, Ahoy 2021 & Cancer Deal Trends
|
Jan 05, 2021 |
Ep. 37 - 2020's Silver Linings, New Year's Hopes
|
Dec 29, 2020 |
Ep. 36 - Vaccines march forward & CAR Ts move earlier: a BioCentury podcast
|
Dec 15, 2020 |
Ep. 35 - ASH Monday, Biden's Picks & Vaccine Conundrums
|
Dec 08, 2020 |
Ep. 34 - Moderna Moves & Immunocore Breaks Through
|
Dec 01, 2020 |
Ep. 33 - ASH Preview & Long Shot Drug Pricing Rule
|
Nov 24, 2020 |
Ep. 32 - Moderna Times & China's Future
|
Nov 17, 2020 |
Ep. 31 - Pfizer & Biogen: The Good, the bAD and What's Next
|
Nov 10, 2020 |
Ep. 30 - ICER's Influence and Election Effects
|
Nov 03, 2020 |
Ep. 29 - SPACs & Vax
|
Oct 27, 2020 |
Ep. 28 - FDA's Future & China Summit Preview
|
Oct 20, 2020 |
Ep. 27 - CRISPR advances and mega-IPOs: a BioCentury podcast
|
Oct 13, 2020 |
Ep. 26 - Treating Trump & BMS's $13B MyoKardia buy
|
Oct 06, 2020 |
Ep. 25 - Alzheimer Milestones & Vaccine Politics
|
Sep 29, 2020 |
Ep. 24 - Azar's Memo & Biotech's Deals
|
Sep 22, 2020 |
Ep. 23 - $21B Deal by Gilead, None by PhRMA
|
Sep 15, 2020 |
Ep. 22 - Back to School, Behind the Scenes
|
Sep 09, 2020 |
Ep. 21 - FDA’s Credibility on the Line, plus Biotech’s Venture Wave
|
Sep 01, 2020 |
Ep. 20 - Politics & Plasma
|
Aug 25, 2020 |
Ep. 19 - I Want KaNDy, Plus Sputnik V & M&A amid COVID-19
|
Aug 17, 2020 |
Ep. 18 - BIOEquality, Data Sharing and Deals
|
Aug 10, 2020 |
Ep. 17 - Warp Speed, Decentralized Trials & SPACs
|
Aug 03, 2020 |
Ep. 16 - Trump's Ultimatum, RADx & Preclinical IPOs
|
Jul 27, 2020 |
Ep. 15 - Vaccine Hopes, the Shifting Biopharma Workplace & Blueprint's Dx Deal
|
Jul 21, 2020 |
Ep. 14 - Investor Sentiment, HCQ Redux and Attacking AMR
|
Jul 14, 2020 |
Ep. 13 - Nuances of NASH, COVID Vaccines and Real-World Data
|
Jul 06, 2020 |
Ep. 12 - Remdesivir's Price, RWD’s Moment & A Genomics Breakup
|
Jun 29, 2020 |
Ep. 11 - Funding U.K. Biotechs, plus Global Vaccine Access
|
Jun 23, 2020 |
Ep. 10 - EUAs, ACTIV & M&A
|
Jun 16, 2020 |
Ep. 9 - IPOs, Vaccines & BIO's New Leader
|
Jun 08, 2020 |
Ep. 8 - Financing Flurry & Purchasing Pools
|
Jun 01, 2020 |
Ep. 7 - FDA takes on COVID-19, plus ASCO's breakthroughs
|
May 27, 2020 |
Ep. 6 - New Faces for COVID-19’s Next Phase, ASCO’s Hot Topics
|
May 19, 2020 |
Ep. 5 - Master Protocols, EUAs and Rick Bright: BioCentury editors on COVID-19
|
May 12, 2020 |
Ep. 4 - End of the beginning for vaccines and the post-pandemic future
|
May 05, 2020 |
Ep. 3 - Surveying the Landscape for Biopharmas
|
Apr 28, 2020 |
Ep. 2 - Consorting to beat COVID-19
|
Apr 23, 2020 |
Ep. 1 - Racing to Create Countermeasures
|
Apr 22, 2020 |